The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma

Han Sang Kim, Hye Ryun Kim, Gun Min Kim, Hyo Song Kim, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Yun Kyoung Hong, Ji Hee Sung, Sun Mi Kim, Joo Hang Kim, Byoung Chul Cho

Research output: Contribution to journalArticle

2 Citations (Scopus)


Purpose To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. Methods A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m2 on days 1-14 and with cisplatin 70 mg/m2 on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. Results The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/ vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. Conclusions The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a firstline chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.

Original languageEnglish
Pages (from-to)539-546
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Issue number4
Publication statusPublished - 2012 Oct 1


All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this